CRISPR nucleic acid rapid detection technology pCIS suitable for PCR equipment

In 2021, based on the CRISPR detection platform, it was hailed as the "next generation molecular diagnostic technology" by Science magazine in the United States! CRISPR Disrupts Traditional Medicine: Diagnose a disease in just a few minutes on a piece of paper!

Infection seriously endangers human life and health

PCIS - In-hospital solutions for infection

Service target: Clinical infection patients in nearly 2000 tertiary hospitals across the country, including infectious disease departments, respiratory departments, pediatrics, and ICUs, providing timely and accurate diagnosis and treatment for many patients, saving lives and reducing medical costs.

Service model: end-to-end business solutions. Each tertiary hospital sells one technology at a time, and the Quebec Medical Laboratory reports on providing in hospital solutions for rapid pathogen testing in critically ill infected patients.

9/18/27/108 BT-CRISPR Pathogen - Rapid Detection of Pathogens in Critically Infected Patients

Quick: On 9/18/27/108, pathogens and drug resistance typing of critical and severe bacterial infections were identified, achieving a 30 minute rapid hospital examination

Sensitivity: Clear clinical significance, high sensitivity, and moderate price,

Excellent: In terms of clinical emergency monitoring, it is superior to mNGS and tNGS for pan bacterial testing

High sensitivity detection of pathogens in critical illness such as pneumonia, sepsis, and meningitis is superior to mNGS and tNGS pan bacterial tests.

Rapid detection of pathogens in critically infected patients

1. PCIS: RPA-CRISPR nucleic acid rapid detection technology applicable to all PCR instruments, with a full process of 30 minutes and a single copy of the detection limit.

2. Exclusive patented PCR reaction sleeve (including reagents), bottom RPA microchip, upper CRISPR microchip. The cover is not opened throughout the entire process, and there is no pollution.

3. The reaction sleeves of RPA and CRISPR microchips using exclusive freeze-drying technology are stored at room temperature for 1 year.

4. Only three pieces of nucleic acid extraction equipment, handheld centrifuge, and PCR instrument are required, without liquid configuration, greatly reducing equipment and operator requirements.

5. The cost of pCIS is low, and medical institutions at or above the county level are equipped with a large number of PCR machines, which have the key application conditions for rapid detection of infectious pathogens.

6. Original RPA-CRISPR special room temperature micro core sleeve, equipped with conventional PCR instrument for use

Fast detection speed, high accuracy, and wide coverage

Applicable population: hospitalized patients with refractory or critical infections, especially ICU or acute infection patients

Technical comparison